Analysis of argentinated peptide complexes using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry: Peptide = oxytocin, arg(8) -vasopressin, bradykinin, bombesin, somatostatin, neurotensin

Binding of Cu+ and Cu2+ with peptides: Peptides = oxytocin, Arg8 -vasopressin, bradykinin, angiotensin-I, substance-P, somatostatin, and neurotensin

The intrinsic binding ability of 7 natural peptides (oxytocin, arg⁸ -vasopressin, bradykinin, angiotensin-I, substance-P, somatostatin, and neurotensin) with copper in 2 different oxidation states (Cu^I/II ) derived from different Cu^+/2+ precursor sources have been investigated for their charge-dependent binding characteristics. The peptide-Cu^I/II complexes, [M - (n-1)H + nCu^I ] and [M - (2n-1)H + nCu^II ], are prepared/generated by the reaction of peptides with CuI solution/Cu-target and CuSO₄ solution and are analyzed by using matrix-assisted laser desorption/ionization (MALDI) time-of-flight mass spectrometry. The MALDI mass spectra of both [M - (n-1)H + nCu^I ] and [M - (2n-1)H + nCu^II ] complexes show no mass shift due to the loss of ─H atoms in the main chain ─NH of these peptides by Cu⁺ and Cu²⁺ deprotonation. The measured m/z value indicates the reduction of Cu^I/II oxidation state into Cu⁰ during MALDI processes. The number and relative abundance of Cu⁺ bound to the peptides are greater compared with the Cu²⁺ bound peptides. Oxytocin, arg⁸ -vasopressin, bradykinin, substance-P, and somatostatin show the binding of 5Cu⁺ , and angiotensin-I and neurotensin show the binding of 7Cu⁺ from both CuI and Cu targets, while bradykinin shows the binding of 2Cu²⁺ , oxytocin, arg⁸ -vasopressin, angiotensin-I, and substance-P; somatostatin shows the binding of 3Cu²⁺ ; and neurotensin shows 4Cu²⁺ binding. The binding of more Cu⁺ with these small peptides signifies that the bonding characteristics of both Cu⁺ and Cu²⁺ are different. The amino acid residues responsible for the binding of both Cu⁺ and Cu²⁺ in these peptides have been identified based on the density functional theory computed binding energy values of Cu⁺ and the fragment transformation method predicted binding preference of Cu²⁺ for individual amino acids.

Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy

Lung cancer, claiming millions of lives annually, has the highest mortality rate worldwide. This advocates the development of novel cancer therapies that are highly toxic for cancer cells but negligibly toxic for healthy cells. One of the effective treatments is targeting overexpressed surface receptors of cancer cells with receptor-specific drugs. The receptors-in-focus in the current review are the G-protein coupled receptors (GPCRs), which are often overexpressed in various types of tumors. The peptide subfamily of GPCRs is the pivot of the current article owing to the high affinity and specificity to and of their cognate peptide ligands, and the proven efficacy of peptide-based therapeutics. The article summarizes various ectopically expressed peptide GPCRs in lung cancer, namely, Cholecystokinin-B/Gastrin receptor, the Bombesin receptor family, Bradykinin B1 and B2 receptors, Arginine vasopressin receptors 1a, 1b and 2, and the Somatostatin receptor type 2. The autocrine growth and pro-proliferative pathways they mediate, and the distinct tumor-inhibitory effects of somatostatin receptors are then discussed. The next section covers how these pathways may be influenced or 'corrected' through therapeutics (involving agonists and antagonists) targeting the overexpressed peptide GPCRs. The review proceeds on to Nano-scaled delivery platforms, which enclose chemotherapeutic agents and are decorated with peptide ligands on their external surface, as an effective means of targeting cancer cells. We conclude that targeting these overexpressed peptide GPCRs is potentially evolving as a highly promising form of lung cancer therapy.

Neuropeptides in Obesity and Metabolic Disease

BACKGROUND

The global rise in the prevalence of obesity and associated comorbidities such as type 2 diabetes, cardiovascular disease, and cancer represents a major public health concern.

CONTENT

Studies in rodents with the use of global and targeted gene disruption, and mapping of neurocircuitry by using optogenetics and designer receptors exclusively activated by designer drugs (DREADDs) have greatly advanced our understanding of the neural control of body weight. In conjunction with analytical chemistry techniques involving classical immunoassays and mass spectrometry, many neuropeptides that are key to energy homeostasis have been identified. The actions of neuropeptides are diverse, from paracrine modulation of local neurotransmission to hormonal control of distant target organs.

SUMMARY

Multiple hormones, such as the adipocyte-derived leptin, insulin, and gut hormones, and nutrients signal peripheral energy state to the central nervous system. Neurons in distinct areas of the hypothalamus and brainstem integrate and translate this information by both direct inhibitory/excitatory projections and anorexigenic or orexigenic neuropeptides into actions on food intake and energy expenditure. The importance of these neuropeptides in human energy balance is most powerfully illustrated by genetic forms of obesity that involve neuropeptides such as melanocortin-4-receptor (MC4R) deficiency. Drugs that mimic the actions of neuropeptides are being tested for the treatment of obesity. Successful therapeutic strategies in obesity will require in-depth knowledge of the neuronal circuits they are working in, the downstream targets, and potential compensatory mechanisms.